Profile of brentuximab vedotin and its potential in the treatment of relapsed or refractory Hodgkin lymphoma

Sam Mayes,1 Adam Gibb,1 Tim Illidge1,21The Christie Hospital NHS Foundation, Wilmslow Road, 2School of Cancer and Enabling Sciences, University of Manchester, Manchester Academic Health Sciences Centre, UKAbstract: Treatment of primary refractory and relapsed classical Hodgkin lymphoma remains chall...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Illidge T, Gibb A, Mayes S
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2012
Materias:
Acceso en línea:https://doaj.org/article/779540bde3854435a910b61767fd764a
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:779540bde3854435a910b61767fd764a
record_format dspace
spelling oai:doaj.org-article:779540bde3854435a910b61767fd764a2021-12-02T08:25:20ZProfile of brentuximab vedotin and its potential in the treatment of relapsed or refractory Hodgkin lymphoma1179-9889https://doaj.org/article/779540bde3854435a910b61767fd764a2012-05-01T00:00:00Zhttp://www.dovepress.com/profile-of-brentuximab-vedotin-and-its-potential-in-the-treatment-of-r-a9940https://doaj.org/toc/1179-9889Sam Mayes,1 Adam Gibb,1 Tim Illidge1,21The Christie Hospital NHS Foundation, Wilmslow Road, 2School of Cancer and Enabling Sciences, University of Manchester, Manchester Academic Health Sciences Centre, UKAbstract: Treatment of primary refractory and relapsed classical Hodgkin lymphoma remains challenging, with disappointing results overall and only a minority of patients enjoying a long-term cure. Until recently, antibody therapy has not played any role in the management of this form of Hodgkin lymphoma. The CD30 antigen was first identified in the Hodgkin Reed–Sternberg malignant cell of Hodgkin lymphoma and emerged as a promising potential target for antibody treatment. The first-generation monoclonal anti-CD30 antibodies proved disappointing with little clinical efficacy. More recently, a novel class of antibody-drug conjugates has emerged. Antibody-drug conjugates offer the potential to target tumor tissue more specifically and deliver potent drug therapies with minimal or less systemic toxicity. Brentuximab vedotin (SGN-35) is one such drug of this class and combines an anti-CD30 monoclonal antibody and the antitubulin agent, monomethyl auristatin E. Initial Phase I studies of brentuximab vedotin showed a promising 52% overall response rate in relapsed Hodgkin lymphoma, with minimal toxicity. More recently, the pivotal Phase II study in 102 patients demonstrated an overall response rate of 75% and a complete response rate of 34%. The median duration of response was 6.7 months, but this was extended to 20.5 months in those who achieved a complete response. This review outlines the development of the antibody-drug conjugate, brentuximab vedotin, for relapsed or refractory classical Hodgkin lymphoma.Keywords: Hodgkin lymphoma, brentuximab vedotin, anti-CD30, antibody, conjugateIllidge TGibb AMayes SDove Medical PressarticleDiseases of the blood and blood-forming organsRC633-647.5ENBlood and Lymphatic Cancer: Targets and Therapy, Vol 2012, Iss default, Pp 99-107 (2012)
institution DOAJ
collection DOAJ
language EN
topic Diseases of the blood and blood-forming organs
RC633-647.5
spellingShingle Diseases of the blood and blood-forming organs
RC633-647.5
Illidge T
Gibb A
Mayes S
Profile of brentuximab vedotin and its potential in the treatment of relapsed or refractory Hodgkin lymphoma
description Sam Mayes,1 Adam Gibb,1 Tim Illidge1,21The Christie Hospital NHS Foundation, Wilmslow Road, 2School of Cancer and Enabling Sciences, University of Manchester, Manchester Academic Health Sciences Centre, UKAbstract: Treatment of primary refractory and relapsed classical Hodgkin lymphoma remains challenging, with disappointing results overall and only a minority of patients enjoying a long-term cure. Until recently, antibody therapy has not played any role in the management of this form of Hodgkin lymphoma. The CD30 antigen was first identified in the Hodgkin Reed–Sternberg malignant cell of Hodgkin lymphoma and emerged as a promising potential target for antibody treatment. The first-generation monoclonal anti-CD30 antibodies proved disappointing with little clinical efficacy. More recently, a novel class of antibody-drug conjugates has emerged. Antibody-drug conjugates offer the potential to target tumor tissue more specifically and deliver potent drug therapies with minimal or less systemic toxicity. Brentuximab vedotin (SGN-35) is one such drug of this class and combines an anti-CD30 monoclonal antibody and the antitubulin agent, monomethyl auristatin E. Initial Phase I studies of brentuximab vedotin showed a promising 52% overall response rate in relapsed Hodgkin lymphoma, with minimal toxicity. More recently, the pivotal Phase II study in 102 patients demonstrated an overall response rate of 75% and a complete response rate of 34%. The median duration of response was 6.7 months, but this was extended to 20.5 months in those who achieved a complete response. This review outlines the development of the antibody-drug conjugate, brentuximab vedotin, for relapsed or refractory classical Hodgkin lymphoma.Keywords: Hodgkin lymphoma, brentuximab vedotin, anti-CD30, antibody, conjugate
format article
author Illidge T
Gibb A
Mayes S
author_facet Illidge T
Gibb A
Mayes S
author_sort Illidge T
title Profile of brentuximab vedotin and its potential in the treatment of relapsed or refractory Hodgkin lymphoma
title_short Profile of brentuximab vedotin and its potential in the treatment of relapsed or refractory Hodgkin lymphoma
title_full Profile of brentuximab vedotin and its potential in the treatment of relapsed or refractory Hodgkin lymphoma
title_fullStr Profile of brentuximab vedotin and its potential in the treatment of relapsed or refractory Hodgkin lymphoma
title_full_unstemmed Profile of brentuximab vedotin and its potential in the treatment of relapsed or refractory Hodgkin lymphoma
title_sort profile of brentuximab vedotin and its potential in the treatment of relapsed or refractory hodgkin lymphoma
publisher Dove Medical Press
publishDate 2012
url https://doaj.org/article/779540bde3854435a910b61767fd764a
work_keys_str_mv AT illidget profileofbrentuximabvedotinanditspotentialinthetreatmentofrelapsedorrefractoryhodgkinlymphoma
AT gibba profileofbrentuximabvedotinanditspotentialinthetreatmentofrelapsedorrefractoryhodgkinlymphoma
AT mayess profileofbrentuximabvedotinanditspotentialinthetreatmentofrelapsedorrefractoryhodgkinlymphoma
_version_ 1718398493227220992